Transcranial Direct Current Stimulation for Cognitive Impairment in Multiple Sclerosis
(MS-HDtDCS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether a mild electrical treatment called transcranial Direct Current Stimulation (tDCS) can improve memory in people with multiple sclerosis (MS). The main focus is on enhancing verbal recall, which involves remembering and using words. Participants will receive either the actual tDCS or a sham (inactive) version to determine if there's a noticeable benefit. Those diagnosed with relapsing-remitting multiple sclerosis (RRMS) who struggle with memory retrieval might be suitable for this trial. As an unphased study, this trial allows participants to contribute to valuable research that could lead to new insights into memory improvement for MS patients.
Will I have to stop taking my current medications?
You may need to stop taking certain medications that interact with the study treatment, such as stimulants like dextroamphetamine, amphetamine, modafinil, and armodafinil. If you are on benzodiazepines, you must have been on a stable dose for at least two months before joining the trial.
What prior data suggests that transcranial direct current stimulation is safe for cognitive impairment in multiple sclerosis?
Research has shown that transcranial Direct Current Stimulation (tDCS) is a safe and well-tolerated treatment. Studies have found that this type of brain stimulation does not cause serious side effects. For instance, participants tolerated levels up to 4 milliamps well. This trial uses an even lower level of 1 milliamp, which previous studies have proven safe.
Individuals who have used tDCS report only mild side effects, such as slight tingling on the scalp or some skin redness, which are usually temporary and not harmful. This technique has even been used safely at home for conditions like multiple sclerosis, a disease affecting the brain and spinal cord.
Overall, evidence suggests that tDCS is a safe option for those considering joining this study.12345Why are researchers excited about this trial?
Researchers are excited about using High-Definition Transcranial Direct Current Stimulation (HD-tDCS) for cognitive impairment in multiple sclerosis because it offers a novel, non-invasive approach. Unlike traditional medications that often focus on symptom management through drug-based therapies, HD-tDCS directly targets brain activity by using mild electrical currents to potentially enhance neural connections and improve cognitive function. This method is particularly promising as it might offer a safer alternative with fewer side effects compared to pharmacological treatments. Additionally, the precision of HD-tDCS in targeting specific brain areas makes it a cutting-edge option that could lead to more personalized and effective treatment strategies for patients.
What evidence suggests that transcranial Direct Current Stimulation is effective for cognitive impairment in multiple sclerosis?
Research has shown that transcranial Direct Current Stimulation (tDCS) can improve thinking skills in people with multiple sclerosis (MS). In this trial, participants will receive either active tDCS or sham tDCS. One study found that tDCS improved thinking speed, mood, pain, and tiredness in MS patients. Another study suggested that tDCS might be more effective when combined with brain training exercises. Evidence also indicates that tDCS can help with thinking problems in conditions like schizophrenia and depression. Overall, tDCS appears to be a promising method for addressing thinking challenges in MS.678910
Who Is on the Research Team?
John Hart, Jr, MD
Principal Investigator
University of Texas at Dallas
Are You a Good Fit for This Trial?
This trial is for individuals with relapsing-remitting multiple sclerosis who have trouble retrieving words. They must speak and read English well, not have had a recent MS episode or taken steroids, and can't be on certain medications like benzodiazepines unless stable for two months.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive transcranial direct current stimulation (tDCS) or sham treatment for 20 minutes over 10 sessions
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at immediate and 2-month intervals
Second Round of Treatment (optional)
Selected participants receive a second round of tDCS or sham treatment, followed by immediate and 2-month follow-up assessments
What Are the Treatments Tested in This Trial?
Interventions
- High-Definition Transcranial Direct Current Stimulation
High-Definition Transcranial Direct Current Stimulation is already approved in United States, European Union for the following indications:
- Experimental treatment for cognitive deficits in multiple sclerosis
- Experimental treatment for cognitive deficits in multiple sclerosis
Find a Clinic Near You
Who Is Running the Clinical Trial?
The University of Texas at Dallas
Lead Sponsor
University of Texas Southwestern Medical Center
Collaborator